IPO registrations (S-1, F-1) · Registrants
Decoy Therapeutics Inc.
- SEC CIK
- 1615219 · filings on EDGAR ↗
- Former names
- Salarius Pharmaceuticals, Inc. (2019–2026); Flex Pharma, Inc. (2014–2019)
- Registration
- Form S-1, first filed 2014-12-29, last 2026-10-07; 7 initial registrations, 11 amendments
- Outcome
- Final prospectus filed 2015-01-29; declared effective 2015-01-28; withdrawal requested 2026-06-05
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 2450 HOLCOMBE BLVD, SUITE J-608, Houston, TX 77021
- EIN
- 46-5087339
- Ticker
- DCOY (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Decoy Therapeutics Inc. on the corporate pages
Offering terms
- Proposed price range
- $12.00–$14.00 per share (S-1/A filed 2015-01-20)
- Final price
- $16.00 per share, above the range (424B4 filed 2015-01-29, an initial public offering)
- Shares sold
- 5,400,000
- Gross proceeds
- $86,400,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol FLKS
- Lead underwriters
- Jefferies; Piper Sandler
- Syndicate
- JMP Securities; Cantor Fitzgerald; Roth Capital Partners
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: DECOY THERAPEUTICS INC. Fuzzy (name and state)
- Form 5500 plan sponsor: FLEX PHARMA, INC. EXACT (EIN (EXACT))
- Form D issuer: Salarius Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- SEC filer: Decoy Therapeutics Inc. EXACT (CIK (EXACT))
- Person page: Arnold C Hanish Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Stuart A Randle Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 37
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-12-29 | S-1 | S-1 (registration) | Flex Pharma, Inc. | 0001047469-14-010116 ↗ |
| 2015-01-13 | S-1/A | S-1/A (amendment) | Flex Pharma, Inc. | 0001047469-15-000197 ↗ |
| 2015-01-20 | S-1/A | S-1/A (amendment) | Flex Pharma, Inc. | 0001047469-15-000294 ↗ |
| 2015-01-28 | S-1MEF | S-1MEF (added securities) | Flex Pharma, Inc. | 0001104659-15-005064 ↗ |
| 2015-01-28 | EFFECT | EFFECT (declared effective) | Flex Pharma, Inc. | 9999999995-15-000225 ↗ |
| 2015-01-29 | 424B4 | 424B4 (final prospectus) | Flex Pharma, Inc. | 0001047469-15-000498 ↗ |
| 2016-04-26 | EFFECT | EFFECT (declared effective) | Flex Pharma, Inc. | 9999999995-16-004331 ↗ |
| 2019-04-29 | EFFECT | EFFECT (declared effective) | Flex Pharma, Inc. | 9999999995-19-000890 ↗ |
| 2019-05-17 | EFFECT | EFFECT (declared effective) | Flex Pharma, Inc. | 9999999995-19-001144 ↗ |
| 2020-01-10 | S-1 | S-1 (registration) | Salarius Pharmaceuticals, Inc. | 0001193125-20-005401 ↗ |
| 2020-01-28 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001193125-20-016222 ↗ |
| 2020-02-06 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001193125-20-025727 ↗ |
| 2020-02-06 | EFFECT | EFFECT (declared effective) | Salarius Pharmaceuticals, Inc. | 9999999995-20-000274 ↗ |
| 2020-02-07 | S-1MEF | S-1MEF (added securities) | Salarius Pharmaceuticals, Inc. | 0001193125-20-027299 ↗ |
| 2020-02-10 | 424B4 | 424B4 (final prospectus) | Salarius Pharmaceuticals, Inc. | 0001193125-20-028933 ↗ |
| 2021-02-01 | EFFECT | EFFECT (declared effective) | Salarius Pharmaceuticals, Inc. | 9999999995-21-000371 ↗ |
| 2022-06-23 | EFFECT | EFFECT (declared effective) | Salarius Pharmaceuticals, Inc. | 9999999995-22-001859 ↗ |
| 2022-08-16 | EFFECT | EFFECT (declared effective) | Salarius Pharmaceuticals, Inc. | 9999999995-22-002398 ↗ |
| 2023-06-06 | EFFECT | EFFECT (declared effective) | Salarius Pharmaceuticals, Inc. | 9999999995-23-001659 ↗ |
| 2024-12-16 | S-1 | S-1 (registration) | Salarius Pharmaceuticals, Inc. | 0001615219-24-000098 ↗ |
| 2024-12-27 | EFFECT | EFFECT (declared effective) | Salarius Pharmaceuticals, Inc. | 9999999995-24-003936 ↗ |
| 2025-01-21 | S-1 | S-1 (registration) | Salarius Pharmaceuticals, Inc. | 0001628280-25-001947 ↗ |
| 2025-04-17 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001628280-25-018065 ↗ |
| 2025-05-22 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001628280-25-027131 ↗ |
| 2025-06-16 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001628280-25-031631 ↗ |
| 2025-07-31 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001628280-25-036892 ↗ |
| 2025-08-08 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001628280-25-039090 ↗ |
| 2025-09-23 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001628280-25-042500 ↗ |
| 2025-10-21 | S-1/A | S-1/A (amendment) | Salarius Pharmaceuticals, Inc. | 0001628280-25-045619 ↗ |
| 2025-11-12 | 424B4 | 424B4 (final prospectus) | Salarius Pharmaceuticals, Inc. | 0001628280-25-051365 ↗ |
| 2026-06-05 | RW | RW (withdrawal request) | Decoy Therapeutics Inc. | 0001193125-26-259729 ↗ |
| 2026-06-15 | S-1 | S-1 (registration) | Decoy Therapeutics Inc. | 0001193125-26-269891 ↗ |
| 2026-06-24 | EFFECT | EFFECT (declared effective) | Decoy Therapeutics Inc. | 9999999995-26-002113 ↗ |
| 2026-07-10 | S-1 | S-1 (registration) | Decoy Therapeutics Inc. | 0001193125-26-300954 ↗ |
| 2026-07-17 | EFFECT | EFFECT (declared effective) | Decoy Therapeutics Inc. | 9999999995-26-002352 ↗ |
| 2026-10-07 | S-1 | S-1 (registration) | Decoy Therapeutics Inc. | 0001193125-26-417053 ↗ |
| 2026-10-16 | EFFECT | EFFECT (declared effective) | Decoy Therapeutics Inc. | 9999999995-26-003278 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-01-20 | S-1/A | registration statement | $12.00–$14.00 | $13.00 | 4,615,000 | $59,995,000 | Nasdaq FLKS | 5 | primary document; range, price sentence, shares headline, proceeds computed, cover names 5 | document ↗ |
| 2015-01-29 | 424B4 | final prospectus | $16.00 | 5,400,000 | $86,400,000 | Nasdaq FLKS | 5 | primary document; price sentence, shares headline, proceeds table, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Cermak Jennifer | Officer | VP Program Management | 1 | 2015 | |
| Hadfield Robert | Officer | General Counsel & Secretary | 3 | 2015–2017 | |
| HAHN MARINA | Officer | President, Consumer; President, Consumer Goods | 2 | 2015 | |
| HUTT PETER BARTON | Director | 7 | 2015–2018 | ||
| KOZIN MARC D | Director | 6 | 2015–2018 | ||
| Longwood Fund II, L.P. | TenPercentOwner | 6 | 2015–2018 | ||
| McCabe John P. | Officer | Chief Financial Officer; VP of Finance & Treasurer | 6 | 2015–2018 | |
| RANDLE STUART A | Director | 5 | 2015–2018 | person page Fuzzy | |
| SCULLEY JOHN | Director | 6 | 2015–2016 | ||
| Wessel Thomas | Officer | Chief Medical Officer | 5 | 2015–2018 | |
| Westphal Christoph H | Director,Officer; Director,Officer,TenPercentOwner; Director,TenPercentOwner; TenPercentOwner | President and CEO | 67 | 2015–2018 | |
| Woo Elizabeth | Officer | SVP, Investor Relations; VP, Investor Relations | 5 | 2015–2018 | |
| MacKinnon Roderick | Director | 5 | 2015–2017 | ||
| CAPELLO JEFFREY D | Director | 4 | 2015–2017 | ||
| Lindemann Katharine | Officer | Chief Operating Officer | 4 | 2015–2017 | |
| PEREZ ROBERT J | Director | 4 | 2015–2017 | ||
| Stacy Michelle | Director | 6 | 2016–2018 | ||
| McVicar William K. | Director; Director,Officer; Officer | President and CEO; President, R&D | 15 | 2017–2026 | |
| Tung Roger D | Director | 3 | 2017–2018 | ||
| Boston Foundation, Inc. | TenPercentOwner | 4 | 2018–2019 | ||
| Arthur David J. | Director,Officer | Chief Executive Officer | 22 | 2019–2024 | |
| Burleson Tess | Director | 11 | 2019–2026 | ||
| Chuang Pao-Yu | Officer | Controller | 2 | 2019 | |
| HANISH ARNOLD C | Director | 20 | 2019–2026 | person page Fuzzy | |
| Jordan Scott | Officer | Chief Business Officer; Chief Financial Officer | 4 | 2019–2020 | |
| Lammers Paul | Director | 8 | 2019–2026 | ||
| McCreedy Bruce J Jr. | Director | 9 | 2019–2024 | ||
| Northrup Jonathan P | Director | 5 | 2019–2020 | ||
| Rosenblum Mark J | Officer | Chief Financial Officer; Exec VP Finance, CFO; Exec VP Finance, Interim CFO | 23 | 2019–2026 | |
| Lieber Jonathan I | Director | 8 | 2020–2026 | ||
| Hibner Barbara Louise | Officer | Chief Scientific Officer | 2 | 2025–2026 | |
| Marschel Peter Klaus | Officer | Chief Business Officer | 2 | 2025–2026 | |
| PIERCE FREDERICK II | Officer | Chief Executive Office; Chief Executive Officer | 2 | 2025–2026 | |
| Gauthier Patricia G. | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-12-27 | Salarius Pharmaceuticals, Inc. | Biotechnology | $10,000,000 | $0 | 1 | 1 |
| 2023-05-25 | Salarius Pharmaceuticals, Inc. | Biotechnology | $6,000,000 | $6,000,000 | 1 | 1 |
| 2022-05-05 | Salarius Pharmaceuticals, Inc. | Biotechnology | $2,334,859 | $2,334,859 | 4 | 1 |
| 2014-08-06 | Flex Pharma, Inc. | Biotechnology | $22,000,000 | $16,224,982 | 20 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | DECOY THERAPEUTICS INC. | TX | State business registries | name and state |
| Plan sponsor | FLEX PHARMA, INC. | TX | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Salarius Pharmaceuticals, Inc. | TX | Form D private offerings | CIK (EXACT) |
| SEC filer | Decoy Therapeutics Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | FLEX PHARMA, INC. | EIN (EXACT) | ||
| Person page | Arnold C Hanish | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Stuart A Randle | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, TX first:
- INTROGEN THERAPEUTICS INC TX
- LEXICON PHARMACEUTICALS, INC. TX
- FILANA THERAPEUTICS, INC. TX
- Marker Therapeutics, Inc. TX
- TANOX INC TX
- LUMOS PHARMA, INC. TX
- BIO-PATH HOLDINGS, INC. TX
- Savara Inc TX
- Altrazeal Life Sciences Inc. TX
- Molecular Templates, Inc. TX
In other datasets, the same topic (Health) in TX:
- Nonprofit: AARON ALEXANDERS CLUB NICU (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health